Cui et al. demonstrated that lncRNA-HEIH promoted CRC tumorigenesis through counteracting miR-939–mediated transcriptional repression of Bcl-xL, and suggested that lncRNA-HEIH may serve as a prognostic biomarker and therapeutic target for CRC [36]. The gene discussed is BCL2L1; the disease is colorectal carcinoma.